<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article242</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ANNEXA" style="display:block; margin-bottom:10px;">ANNEXA Original</a></li>
<h2><strong>ANNEXA</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Reversal of Anticoagulation". The New England Journal of Medicine. 2015. 373:2413-2424.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does andexanet rapidly reverse the anticoagulation effects of apixaban and rivaroxaban in older healthy participants without causing serious adverse or thrombotic events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Andexanet rapidly reversed the anticoagulation effect of apixaban and rivaroxaban in older participants with no evidence of serious adverse events or clinical thrombosis.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
At the time of study publication, there were no existing guidelines for the reversal of factor Xa inhibitors with andexanet alfa. Further clinical trials in patients with acute major bleeding on factor Xa inhibitors are required to provide data for formal guideline recommendations.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Two part, randomized, double-blind, placebo-controlled studies in healthy older volunteers receiving apixaban or rivaroxaban. <br/><br/><br/>
Mean age: 57.9 years<br/>
- 39% female<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Healthy volunteers aged 50 to 75 years.<br/>
<br/>
Inclusion Criteria:<br/>
- Participants who received the highest approved doses of apixaban (5 mg twice daily) or rivaroxaban (20 mg daily) to steady-state levels.<br/>
<br/>
Exclusion Criteria:<br/>
Not explicitly defined in the summary, but typically would include allergies to study drugs or active bleeding.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Andexanet given as an intravenous bolus or bolus plus a 2-hour infusion after steady state dosing of either apixaban or rivaroxaban to achieve maximum anticoagulation effect.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome:<br/><br/>
<br/>
Secondary Outcomes:<br/>
- At least 80% reversal of antiâ€“factor Xa activity in nearly all participants given andexanet (P&lt;0.001 compared to placebo).<br/><br/>
- Significant reduction of unbound apixaban and rivaroxaban concentrations with andexanet compared to placebo (P&lt;0.001).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The study population consisted of healthy older adults, which may not accurately represent the characteristics of patients typically receiving anticoagulation therapy.<br/>
- The efficacy of andexanet for urgent reversal in the context of active bleeding events or emergencies requiring rapid anticoagulant reversal was not assessed.<br/>
- There were transient increases in d-dimer and prothrombin fragments 1 and 2, potential signs of coagulopathy, which could be concerning although no clinical thrombosis occurred.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Portola Pharmaceuticals, Bayer, Bristol-Myers Squibb, Johnson &amp; Johnson, and Pfizer.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
